| Peck-Radosavljevic, Markus |
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein |
|
|
| Recruiting | 3 | 160 | Europe, Canada, US, RoW | Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride | Takeda, Takeda Development Center Americas, Inc. | Alpha1-Antitrypsin Deficiency | 03/27 | 03/29 | | |
| Kautzky-Willer, Alexandra |
Test2Func, NCT03851627: Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism |
|
|
| Recruiting | 4 | 32 | Europe | Testosterone Undecanoate, Nebido, Placebo, oily solution, Nebido like Placebo | Alexandra Kautzky-Willer, Bayer | Fatty Liver, Overweight/Obesity, Prediabetes/Type2 Diabetes Mellitus, Hypogonadism, Male | 09/28 | 12/28 | | |
NCT02817360: NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients |
|
|
| Recruiting | 4 | 2400 | Europe, RoW | RAS-antagonist and beta-blocker up-to maximal dosages, Enalapril 40mg/d, Ramipril 10mg/d, Lisinopril 40mg/d, Cilazapril 5mg/d, Perindopril 8mg/d, Captopril 150mg/d, Spirapril 24mg/d, Quinapril 40mg/d, Trandolapril 4mg/d, Zofenopril 60mg/d, Fosinopril 40mg/d, Candesartan 32mg/d, Valsartan 320mg/d, Irbesartan 300mg/d, Losartan 150mg/d, Eprosartan 800mg/d, Bisoprolol 10mg/d, Metoprololsuccinat 200mg/d, Carvedilol 50mg/d (100mg/d if weight is > 85kg), Nebivolol 10mg/d, RAS-antagonist and beta-blocker none or at stable dose | Martin Huelsmann | Heart Diseases, Diabetes Mellitus, Type 2 | 12/25 | 12/26 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Overweight and Obesity | 02/29 | 02/29 | | |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Recruiting | 3 | 2620 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 04/25 | 12/25 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
NCT06245681: Effects of Cross-sex Hormone Treatment on Cardiac Function, Myocardial and Hepatic Fat Content |
|
|
| Recruiting | N/A | 40 | Europe | gender affirming hormone therapy | Medical University of Vienna | Gender Dysphoria | 10/25 | 10/25 | | |
NCT06291675: Gender-Affirming Hormone Therapy and Its Impact on Myocardial Mass and Cardiac Function, Heart, Liver and Pancreatic Fat Content |
|
|
| Recruiting | N/A | 50 | Europe | gender-affirming hormone therapy | Medical University of Vienna | Gender Dysphoria, Hormone Therapy Induced Morphologic Change | 03/26 | 03/33 | | |
| Hengstenberg, Christian |
EUROSHOCK, NCT03813134: Testing the Value of Novel Strategy and Its Cost Efficacy in Order to Improve the Poor Outcomes in Cardiogenic Shock |
|
|
| Recruiting | N/A | 428 | Europe | Percutaneous coronary intervention (PCI), Pharmacological Support, VA-ECMO, Veno-Arterial Extra Corporeal Membrane Oxygenation. | University of Leicester, European Commission, University of Glasgow, KU Leuven, University of East Anglia, Deutsches Herzzentrum Muenchen, A.O. Ospedale Papa Giovanni XXIII, Chalice Medical Ltd, Ludwig-Maximilians - University of Munich, University of Tromso, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Paula Stradina Liniska Universitates, Accelopment AG, Universiteit Antwerpen, Cardiovascular European Research Centre (CERC) | Cardiogenic Shock | 03/23 | 02/24 | | |
| Recruiting | N/A | 150 | Europe | Streamlining of the pre-procedural patient pathway | Institut für Pharmakologie und Präventive Medizin, Edwards Lifesciences | Transcatheter Aortic Valve Implantation (TAVI) | 08/24 | 01/25 | | |
| Recruiting | N/A | 150 | Europe, Canada, RoW | Elective redo transcatheter aortic valve implantation (redo-TAVI), redo-TAVI | Institut für Pharmakologie und Präventive Medizin, Edwards Lifesciences | Aortic Valve Stenosis, Structural Valve Deterioration, Structural Valve Degeneration | 09/25 | 12/26 | | |
NCT05114850: Retrospective Prospective Multicentric Clinical Follow up of Patients After Being Treated With TricValve® |
|
|
| Recruiting | N/A | 450 | Europe | | P+F Products + Features GmbH | Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Insufficiency, Heart Failure, Heart Diseases, Heart Valve Diseases | 12/25 | 12/28 | | |
| Recruiting | N/A | 650 | Europe, Canada, Japan, US, RoW | Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT) | Medtronic Cardiovascular | Moderate Aortic Valve Stenosis | 02/26 | 12/34 | | |
| Recruiting | N/A | 400 | Europe, Canada, US | Evolut R/PRO bioprosthesis, Edwards Sapien S3/Ultra bioprosthesis | Erasmus Medical Center | Valve Heart Disease | 05/26 | 05/26 | | |
| Reinisch, Walter |
ASPIRE, NCT04118088: A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula |
|
|
| Active, not recruiting | 4 | 50 | Europe, RoW | Darvadstrocel, Alofisel, Cx601 | Takeda, Takeda Development Center Americas, Inc. | Crohn's Disease, Complex Perianal Fistula | 03/26 | 03/26 | | |
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 160 | Europe, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis, Ulcerative Colitis Chronic | 12/24 | 03/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 01/25 | 12/26 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
| Trauner, Michael |
| Recruiting | 4 | 192 | Europe | Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector, Jardiance(R), Ozempic(R), Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide, Jardiance(R), Placebo matching empagliflozin and placebo pen injector matching semaglutide, Control / Placebo | The Deutsche Diabetes Forschungsgesellschaft e.V., Boehringer Ingelheim, German Center for Diabetes Research, Federal Ministry of Health, Germany, Ministry of Innovation, Science and Research in North Rhine-Westphalia, Novo Nordisk A/S | Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD) | 01/25 | 12/25 | | |
| Recruiting | 3 | 300 | Europe | norUrsodeoxycholic Acid, NUC | Dr. Falk Pharma GmbH | Primary Sclerosing Cholangitis | 04/21 | 12/23 | | |
| Active, not recruiting | 2 | 72 | Europe, RoW | Obeticholic acid, Bezafibrate 200 MG, OCA Placebo, Bezafibrate 200 mg Placebo, Bezafibrate 400 MG, Bezafibrate 400 mg Placebo, OCA, Bezafibrate | Intercept Pharmaceuticals | Primary Biliary Cholangitis | 10/25 | 12/25 | | |
| Recruiting | 2 | 363 | Europe | norUrsodeoxycholic acid, norucholic acid, norUDCA, NCA | Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH, | Nonalcoholic Steatohepatitis | 01/25 | 04/25 | | |
ADLH, NCT03897218: Dietary Modulation of Intestinal Microbiota as Trigger of Liver Health: Role of Bile Acids - "A Diet for Liver Health" |
|
|
| Completed | N/A | 84 | Europe | oatmeal flakes with prebiotic food supplements, millet flakes | RWTH Aachen University | NASH - Nonalcoholic Steatohepatitis | 04/22 | 04/22 | | |
| Singer, Christian |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Recruiting | 3 | 860 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 04/24 | 08/27 | | |
| Recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 10/24 | 06/27 | | |
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease |
|
|
| Active, not recruiting | 3 | 40 | Europe, Canada, Japan, US, RoW | Niraparib, Placebo | GlaxoSmithKline | Neoplasms, Breast | 03/25 | 08/29 | | |
|
TAXIS, NCT03513614: Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer |
|
|
| Recruiting | 3 | 1500 | Europe, RoW | Tailored axillary surgery - both Arms, Radiotherapy - Arm A, Radiotherapy - Arm B | University Hospital, Basel, Switzerland, ETOP IBCSG Partners Foundation, Austrian Breast Cancer Study Group | Node-positive Breast Cancer | 12/29 | 12/36 | | |
NCT03301493: Genomic Testing and Resulting Medical Decisions |
|
|
| Recruiting | N/A | 1000 | Europe | Genomic testing | Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, AstraZeneca | Cancer of Unknown Origin, Cancer Refractory, Cancer of Stomach, Cancer Head Neck, Cancer of Skin, Cancer, Lung, Cancer Colorectal, Cancer of Esophagus, Cancer, Bladder, Cancer, Uterus, Cancer Cervix, Cancer Liver, Cancer, Kidney, Cancer, Breast, Hematologic Neoplasms | 12/24 | 12/24 | | |
| Recruiting | N/A | 3000 | Europe | | Arbeitsgemeinschaft medikamentoese Tumortherapie, Hoffmann-La Roche, Daiichi Sankyo, Pfizer, Novartis, Caris Life Science, AstraZeneca, Seagen Inc., Eli Lilly and Company | Breast Cancer, Breast Carcinoma, Breast Tumor | 06/25 | 06/25 | | |
| Kim, Hyun Soo |
COALA, NCT05383183: Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's Disease |
|
|
| Recruiting | 4 | 630 | RoW | Choline Alfoscerate 400mg, Placebo | Daewoong Bio Inc. | Alzheimer Disease | 06/25 | 12/25 | | |
NCT05803941: Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer |
|
|
| Recruiting | 4 | 700 | US | AAA617, lutetium (177Lu) vipivotide tetraxetan, [177Lu]Lu-PSMA-617, 177Lu-PSMA-617 | Novartis Pharmaceuticals | Prostate Cancer | 07/33 | 07/33 | | |
| Terminated | 3 | 372 | Europe, US, RoW | Pamrevlumab, FG-3019, Placebo | FibroGen | Idiopathic Pulmonary Fibrosis | 09/23 | 09/23 | | |
|
| Active, not recruiting | 3 | 380 | Europe, Canada, Japan, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo | Chinook Therapeutics U.S., Inc. | IgA Nephropathy, Immunoglobulin A Nephropathy | 09/23 | 12/26 | | |
PROUD, NCT05666804: Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy |
|
|
| Recruiting | 3 | 160 | RoW | Brolucizumab 6mg, Beovu | Novartis Pharmaceuticals | Macular Polypoidal Choroidal Vasculopathy (PCV) | 09/25 | 09/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 01/25 | 12/26 | | |
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 3 | 576 | Canada, US | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | 06/25 | 06/25 | | |
|
|
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC |
|
|
| Active, not recruiting | 3 | 1144 | Europe, Canada, Japan, US, RoW | 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT | Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc. | Prostatic Neoplasms | 07/25 | 02/26 | | |
|
| Active, not recruiting | 3 | 202 | US | N-acetyl cysteine, NAC, Placebo | Weill Medical College of Cornell University, University of Virginia, University of Michigan, Pulmonary Fibrosis Foundation, University of Washington, National Heart, Lung, and Blood Institute (NHLBI), Three Lakes Foundation | Idiopathic Pulmonary Fibrosis | 12/25 | 12/25 | | |
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis |
|
|
| Recruiting | 3 | 698 | Canada, US | Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer | United Therapeutics | Progressive Pulmonary Fibrosis, Interstitial Lung Disease | 11/27 | 11/27 | | |
NCT03132974: Evaluation of Efficacy and Safety of Single and Multiple Therapy of Herbal Medicine/Chuna Therapy on Non-specific Chronic Low Back Pain: A Study Protocol for Multicenter, 3-arm, Randomized, Single Blinded, Parallel Group, Incomplete Factorial Design, Pilot Study - |
|
|
| Recruiting | 2/3 | 150 | RoW | Sogyeonghwalhyeol-tang granule, Sogyeonghwalhyeol-tang granule with manipulation procedure, Placebo with manipulation procedure | Gachon University Gil Oriental Medical Hospital, Daejeon University, Semyung University Korean Medicine Hospital in Chungju, Woosuk University Oriental Medical Center | Chronic Low Back Pain | 12/21 | 12/21 | | |
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 207 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo | Takeda | Ulcerative Colitis | 09/26 | 08/27 | | |
NCT04541173: Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC) |
|
|
| Terminated | 2 | 6 | US | Y-90 TARE, Atezolizumab, Tecentriq, Bevacizumab, Avastin | Aiwu Ruth He, MD, Georgetown University, Genentech, Inc. | Hepatocellular Carcinoma | 06/23 | 06/23 | | |
| Active, not recruiting | 2 | 357 | Europe, Canada, US | TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar | Takeda | Celiac Disease | 05/25 | 05/25 | | |
NCT04162665: Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer |
|
|
| Recruiting | 2 | 36 | US, RoW | Adaptive short course radiation therapy, Standard of care chemotherapy regimen | Washington University School of Medicine, Viewray Inc. | Gastric Adenocarcinoma | 04/26 | 04/27 | | |
NCT04331041: Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma |
|
|
| Recruiting | 2 | 42 | US | Adaptive stereotactic body radiation therapy, Adaptive SBRT, Defactinib, VS-6063, PF-04554878, Tumor biopsy, Research blood draw | Washington University School of Medicine, National Cancer Institute (NCI), Verastem, Inc. | Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma | 12/25 | 12/26 | | |
NCT04166318: Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study |
|
|
| Recruiting | 2 | 252 | US | Capecitabine, Ro 09-1978/000, Xeloda, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Mitomycin, Ametycine, MITO, MITO-C, Mito-Medac, Mitocin, Mitocin-C, Mitolem, Mitomycin C, Mitomycin-C, Mitomycin-X, Mitomycine C, Mitosol, Mitozytrex, Mutamycin, Mutamycine, NCI-C04706, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) | Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8 | 12/29 | 12/29 | | |
NCT02899091: Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease |
|
|
| Active, not recruiting | 1/2 | 24 | RoW | CB-AC-02, Placebo | CHABiotech CO., Ltd | Alzheimer's Disease | 12/24 | 12/24 | | |
NCT05877430: Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer |
|
|
| Recruiting | 1/2 | 160 | RoW | CJRB-101, Pembrolizumab injection | CJ Bioscience, Inc. | NSCLC, HNSCC, Melanoma, Metastatic Cancer, Advanced Solid Tumor, Advanced Cancer | 07/26 | 10/27 | | |
NCT05413850: Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection |
|
|
| Recruiting | 1/2 | 150 | Europe, US | 177Lu-rhPSMA-10.1 injection, 177Lu-rhPSMA-10.1, 18F-rhPSMA-7.3 injection, 18F-rhPSMA-7.3 | Blue Earth Therapeutics Ltd, PSI CRO | Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms, Prostatic Neoplasms, Prostatic Diseases | 08/26 | 10/26 | | |
NCT03516708: Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer |
|
|
| Recruiting | 1/2 | 39 | US | Epacadostat, INCB024360, Short-course radiation, CAPOX chemotherapy | Washington University School of Medicine, Incyte Corporation, National Cancer Institute (NCI) | Rectal Cancer | 07/27 | 08/30 | | |
|
NCT05039905: SLN Detection With Tc-MSA-ICG in Lung Cancer Patients |
|
|
| Recruiting | 1 | 10 | RoW | 99mTc-MSA-ICG | Korea University Guro Hospital | Lung Cancer | 12/21 | 12/21 | | |
NCT04046575: Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer |
|
|
| Recruiting | 1 | 20 | US | Intensity Modulated Radiation Therapy, IMRT, Carboplatin, Paraplatin, MD Anderson Symptom Inventory (MDASI)-Plus module, EuroQol (EQ-5D), SF-12, MOS Social Support Measure, CES-D, Blood for ctDNA (optional), Blood for SCCA, Paclitaxel, Taxol | Washington University School of Medicine | Esophagus Cancer, Esophageal Cancer, Cancer of the Esophagus | 09/25 | 09/27 | | |
NCT06167941: Identification of Integrin ab Expression in Lung Cancer Patients |
|
|
| Completed | N/A | 61 | RoW | Lung cancer types | Korea University Guro Hospital | Expression of Integrin ανβ3 in Lung Cancer | 09/21 | 11/21 | | |
NCT04441970: The Influence of Head and Neck Position on the Cuff Pressure Using Nasotracheal Tube |
|
|
| Recruiting | N/A | 50 | RoW | Neutral position, Head extension position, Head flexion position, Head rotation position | Yonsei University | Adult Patients Over 20 Years of Age Who Require Intubation of the Nasotracheal Tube to Undergo Oral and Maxillofacial Surgery Under General Anesthesia | 12/20 | 03/21 | | |
NCT04499222: Assessment of Tube Position According to the Changes of Neck Position Between Two Different Types of Nasotracheal Tubes |
|
|
| Not yet recruiting | N/A | 40 | RoW | Portex, Mallinckrodt | Yonsei University | Nasotracheal Intubation | 05/22 | 05/25 | | |
NCT03415919: Collection of Gastrointestinal Malignant and Non-malignant Human Samples |
|
|
| Enrolling by invitation | N/A | 300 | US | no intervention will be given to patients. | University of Texas at Austin | Inflammatory Bowel Diseases, Colo-rectal Cancer | 07/22 | 07/22 | | |
NCT03962374: The Comparison of the Success Rate of the Endotracheal Intubation Between the Stylet and the Frova With Acute Angled Videolaryngoscope |
|
|
| Recruiting | N/A | 166 | RoW | Frova, Stylet | Yonsei University | Anesthesia, General | 05/23 | 06/23 | | |
NCT05255588: A Stool DNA-based SDC2 Methylation Test for the Early Detection of Colorectal Cancer |
|
|
| Recruiting | N/A | 2358 | RoW | EarlyTect® CRC test | Genomictree, Inc., Soon Chun Hyang University, Gangnam Severance Hospital, Kyung Hee University Hospital at Gangdong, Kangbuk Samsung Hospital, Kyung Hee University Hospital, Keimyung University Dongsan Medical Center, Korea University Anam Hospital, Pusan National University Hospital, The Catholic Univ. of Korea Bucheon ST. Mary's Hospital, Samsung Medical Center, Seoul National University Hospital, Asan Medical Center, Wonju Severance Christian Hospital, Severance Hospital | Colorectal Cancer, Advanced Colorectal Neoplasm, Advanced Adenomas, Non-neoplastic Polyps, Non-advanced Adenomas | 02/24 | 02/24 | | |
NCT05571982: Comparison of the Efficacy of Tidal Volume Breathing and Vital Capacity Breathing During High-flow Nasal Oxygen |
|
|
| Not yet recruiting | N/A | 58 | RoW | Tidal volume breathing technique, Vital capacity breathing technique | Yonsei University | Adult Patients 20 Years of Age or Older Who Are Planning to Undergo Surgery Under General Anesthesia | 09/23 | 09/24 | | |
ASSURE, NCT03306901: Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma |
|
|
| Active, not recruiting | N/A | 240 | RoW | Esophagectomy, 5-fluorouracil, 5-FU, Cisplatin, Radiation therapy | Samsung Medical Center, Ministry of Health & Welfare, Korea | Esophageal Cancer | 12/25 | 12/33 | | |
NCT05987007: Sleep Interventions and Neurocognitive Outcomes |
|
|
| Not yet recruiting | N/A | 50 | US | Acoustic slow-wave activity enhancement, Cognitive behavioral therapy for insomnia | New York State Psychiatric Institute, Columbia University | Sleep Disturbance, Amnestic Mild Cognitive Impairment | 12/27 | 12/27 | | |
| Withdrawn | N/A | 10 | NA | Balloon-tipped catheter | Washington University School of Medicine | Esophageal Cancer, Kidney Cancer, Larynx Cancer, Liver Cancer, Lung Cancer, Digestive Organs--Cancer, Intrathoracic--Cancer, Respiratory Organs--Cancer, Pancreas Cancer, Small Intestine Cancer, Stomach Cancer, Colon Cancer, Rectal Cancer | 04/25 | 05/25 | | |
| Recruiting | N/A | 55 | US | Halcyon 4.0 system | Washington University School of Medicine, Varian Medical Systems | Brain Cancer, Head and Neck Cancer, Lung Cancer, Gastric Cancer, Ovarian Cancer, Colon Cancer | 10/24 | 10/24 | | |
| Recruiting | N/A | 10 | US | Proton SBRT | Washington University School of Medicine, The Foundation for Barnes-Jewish Hospital | Solid Tumor | 05/25 | 08/25 | | |
IMPARC, NCT04827732: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in Recurrent Rectal Cancer |
|
|
| Recruiting | N/A | 23 | US | Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy, IMPT, MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine | Washington University School of Medicine | Recurrent Rectal Cancer | 12/25 | 01/26 | | |
| Recruiting | N/A | 10000 | RoW | Biologic or targeted synthetic DMARD, etanercept, adalimumab, infliximab, golimumab, tocilizumab, abatacept, rituximab, ustekinumab, secukinumab, ixekizumab, or biosimilars, tofacitinib, baricitinib, upadacitinib | Seoul National University Hospital | Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis | 12/29 | 06/30 | | |
| Active, not recruiting | N/A | 63 | US | Radiation therapy, FOLFOX regimen, Functional Assessment of Cancer Therapy-Colorectal cancer (FACT-C) questionnaire, Rectal biopsy samples, Blood for ctDNA | Washington University School of Medicine | Adenocarcinoma of the Lower Rectum | 09/24 | 04/26 | | |
| Recruiting | N/A | 46 | RoW | Targeted therapeutic hypothermia, Targeted therapeutic normothermia | Wonju Severance Christian Hospital, National Research Foundation of Korea | Carbon Monoxide Poisoning, Neurologic Sequelae, Hypothermia | 12/24 | 07/25 | | |
| Recruiting | N/A | 134 | US | Daily Adaptive External Beam Radiation Therapy | Varian, a Siemens Healthineers Company, Washington University School of Medicine | Pancreatic Cancer | 02/25 | 02/27 | | |
NCT05369182: Multicenter Registry of Coronary Flow-Derived Indexes for Coronary Microvascular Disease (Multicenter FLOW-CMD Registry) |
|
|
| Recruiting | N/A | 1000 | RoW | Invasive physiologic assessment, Intravascular imaging | Samsung Medical Center, Chonnam National University Hospital, Chosun University Hospital, Seoul National University Bundang Hospital, Seoul St. Mary's Hospital | Coronary Microvascular Disease, Coronary Artery Disease, Ischemic Heart Disease | 06/27 | 06/30 | | |
| Recruiting | N/A | 60 | US | | Washington University School of Medicine, National Cancer Institute (NCI) | Locally Advanced Cervical Carcinoma, Locally Advanced Cervical Cancer, Locally Advanced Pancreas Cancer, Locally Advanced Pancreatic Carcinoma, Locally Advanced Pancreatic Cancer, Cervical Cancer, Pancreas Cancer, Pancreatic Cancer, Cancer of the Cervix, Cancer of the Pancreas | 12/32 | 12/32 | | |
NCT05587114: Comparision of Various Biomarkers Between Peripheral and Pulmonary Blood |
|
|
| Recruiting | N/A | 150 | RoW | frozen blood plasma samples | Korea University Guro Hospital | Lung Cancer, Diagnosis | 12/24 | 12/25 | | |
| Polterauer, Stephan |
| Active, not recruiting | 3 | 568 | Europe, Canada, Japan, US, RoW | tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed | Seagen Inc., Genmab | Cervical Cancer | 07/23 | 08/25 | | |
| Recruiting | 3 | 540 | Europe | Letrozole 2.5mg, Femara, Placebo | Swiss GO Trial Group, AGO Study Group, Arbeitsgemeinschaft Gynaekologische Onkologie Austria, Reliable Cancer Therapies, Krebsliga Schweiz, Stiftung Guido Feger, Hoffmann-La Roche, Helsana AG, Novartis Pharmaceuticals, Anticancer Fund, Belgium | Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC), Low-grade Serous Ovarian Carcinoma (LGSOC), Ovarian Endometrioid Carcinoma | 10/25 | 10/30 | | |
NCT05797831: Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer |
|
|
| Recruiting | 2/3 | 268 | Europe, Canada, US, RoW | Navtemadlin, KRT-232, Navtemadlin Placebo | Kartos Therapeutics, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation | Endometrial Cancer | 08/25 | 07/27 | | |
| Klepetko, Walter |
| Recruiting | N/A | 700 | Europe, Canada, US, RoW | Lung transplant biopsy bites. | University of Alberta | Lung Transplant Rejection | 11/24 | 06/25 | | |
| Active, not recruiting | N/A | 2000 | Europe | patient registry (observation and biomaterial sampling) | Andreas Guenther | Idiopathic Pulmonary Fibrosis, Idiopathic Interstitial Pneumonia, Interstitial Lung Diseases, Diffuse Parenchymal Lung Diseases | 01/25 | 01/40 | | |
| Recruiting | N/A | 60 | Europe | Tissue sampling | Ludwig Boltzmann Institute for Lung Vascular Research, Medical University of Graz, Medical University of Vienna | Pulmonary Hypertension | 12/24 | 06/25 | | |
| Speidl, Walter |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
| chen, yan yan |
HEARTRIP, NCT03809273: Effects of Yangxinshi Pills on the Exercise Tolerance Compared With Trimetazidine in Patients After PCI |
|
|
| Recruiting | 4 | 668 | RoW | Yangxinshi, Trimetazidine, Yangxinshi mimic, Trimetazidine mimic | Shenyang Northern Hospital | Percutaneous Coronary Intervention | 12/20 | 12/20 | | |
NCT05481619: Study of the Effect of Vedolizumab on Intestinal Microecological Changes and Its Efficacy in the Treatment of Ulcerative Colitis |
|
|
| Recruiting | 4 | 30 | RoW | Vedolizumab | Second Affiliated Hospital, School of Medicine, Zhejiang University | Ulcerative Colitis | 01/24 | 01/24 | | |
NCT05205603: Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis |
|
|
| Recruiting | 4 | 438 | RoW | Infliximab, Vedolizumab, Mesalazine | Sixth Affiliated Hospital, Sun Yat-sen University | Ulcerative Colitis, Efficacy, Self, Biologics, Mesalazine | 01/24 | 01/25 | | |
TIGER, NCT04255602: A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients |
|
|
| Recruiting | 4 | 2120 | RoW | Ticagrelor 60mg, Ticagrelor 90mg | Shanghai Tong Ren Hospital, Shanghai Jiao Tong University School of Medicine, Fudan University | Acute Coronary Syndrome, Coronary Stent Implantation | 12/24 | 12/24 | | |
| Active, not recruiting | 3 | 1281 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828, Placebo | Eli Lilly and Company | Ulcerative Colitis | 01/21 | 05/24 | | |
|
|
|
|
| Active, not recruiting | 3 | 1177 | Europe, Canada, Japan, US, RoW | Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC | Eli Lilly and Company | Ulcerative Colitis | 11/21 | 12/24 | | |
|
|
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
TAPER-V, NCT04138706: Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection |
|
|
| Recruiting | 3 | 552 | Canada | Vancomycin, Placebos | McGill University Health Centre/Research Institute of the McGill University Health Centre, Canadian Institutes of Health Research (CIHR) | Clostridium Difficile Infection | 07/24 | 09/24 | | |
NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 12/24 | 02/25 | | |
NCT06434467: The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma |
|
|
| Not yet recruiting | 3 | 83 | RoW | Nelarabine injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | T-lymphoblastic Leukemia, T-lymphoblastic Lymphoma | 12/25 | 05/26 | | |
NCT05181137: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 368 | Europe, US, RoW | SHR0302, Placebo | Reistone Biopharma Company Limited | Ulcerative Colitis | 10/24 | 03/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 01/25 | 12/26 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 06/26 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
NCT03221036: Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis |
|
|
| Recruiting | 3 | 402 | RoW | Vedolizumab IV, Placebo | Takeda | Moderately to Severely Active Ulcerative Colitis | 05/28 | 07/28 | | |
| Recruiting | 2 | 80 | RoW | Activated CIK, CIK | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd., Beijing 302 Hospital | Advanced Liver Cancer | 01/21 | 01/21 | | |
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
NCT04633798: Evaluation of the Efficacy of Intense Pulse Light Combined With Lipiflow in the Treatment of Meibomian Gland Dysfunction |
|
|
| Not yet recruiting | N/A | 100 | NA | IPL/Lipiflow, IPL/MGX | Aier School of Ophthalmology, Central South University | Meibomian Gland Dysfunction | 12/20 | 12/20 | | |
| Completed | N/A | 980 | RoW | Rotational Atherectomy | Beijing Anzhen Hospital, BSC International Medical Trading (Shanghai) Co., Ltd. | Coronary Artery Disease | 12/20 | 01/22 | | |
